CBT-I vs Sleeping Pills: 7 Evidence-Based Reasons Therapy Beats Medication for Chronic Insomnia

This article examines the comparative clinical evidence for Cognitive Behavioral Therapy for Insomnia (CBT-I) versus pharmacological treatment of chronic insomnia disorder, as classified under the International Classification of Sleep Disorders, Third Edition (ICSD-3), which requires symptoms occurring at least three nights per week for a minimum of three months alongside daytime impairment. The article examines Arthur Spielman's 1987 3-P model (predisposing, precipitating, perpetuating factors) as the mechanistic account of how acute insomnia becomes chronic, and reviews the pharmacology and documented long-term risks of benzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone), including the 2023 Beers Criteria designation, fall and fracture risk in older adults, and an approximately 20% increase in dementia risk with long-term use. The four core components of CBT-I (sleep restriction, stimulus control, cognitive restructuring, and sleep hygiene) are reviewed against the recommendation of the American Academy of Sleep Medicine (2021), the American College of Physicians, and the British Association for Psychopharmacology, all of which designate CBT-I as first-line treatment. The article evaluates Trauer et al.'s 2015 Annals of Internal Medicine meta-analysis directly comparing CBT-I to medication, CBT-I's documented efficacy in insomnia comorbid with depression, anxiety, and chronic pain, and the 2025 clinical trial evidence supporting FDA-cleared digital CBT-I platforms. The conclusion offers a practical, evidence-based framework for beginning CBT-I, including realistic timelines and medical clearance considerations.